Cara Therapeutics to Present at November Investor Conferences
November 08 2018 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus and pain by selectively targeting
peripheral kappa opioid receptors, today announced company
management will present a company overview at three investor
conferences in November:
Stifel 2018 Healthcare Conference (New
York)Date: Tuesday, November 13,
2018Time: 9:30 a.m. ET
Jefferies 2018 London Healthcare Conference (London,
UK)Date: Thursday, November 15,
2018Time: 1:20 p.m. GMT+1 (8:20 a.m. ET)
Piper Jaffray 30th Annual Healthcare Conference (New
York)Date: Tuesday, November 27,
2018Time: 2:00 p.m. ET
A live audio webcast of each event can be
accessed under "Events and Presentations" in the News &
Investors section of the Company's website at
www.CaraTherapeutics.com. Archived webcast recordings will be
available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus and pain by
selectively targeting peripheral kappa opioid receptors (KORs).
Cara is developing a novel and proprietary class of product
candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class
KOR agonist that targets the body's peripheral nervous system, as
well as certain immune cells. In Phase 2 trials, KORSUVA injection
has demonstrated statistically significant reductions in itch
intensity and concomitant improvement in quality of life measures
in hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP), and is currently being
investigated in Phase 3 trials in hemodialysis patients with
CKD-aP. Additionally, in a recently completed Phase 2/3 trial in
post-operative patients, I.V. CR845/difelikefalin has demonstrated
reduction in moderate-to-severe pain, while also reducing the
incidence and intensity of nausea and vomiting throughout the
post-operative period.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection.
CR845/difelikefalin is an investigational drug product and its
safety and efficacy have not been fully evaluated by any regulatory
authority.
MEDIA CONTACT: Annie Starr 6 Degrees
973-415-8838 astarr@6degreespr.com
INVESTOR CONTACT: Michael Schaffzin Stern
Investor Relations, Inc. 212-362-1200michael@sternir.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024